Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06295822
Other study ID # CMUH112-REC2-063
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 4, 2024
Est. completion date February 28, 2026

Study information

Verified date April 2024
Source China Medical University Hospital
Contact HSUAN HSUAN WU
Phone +886928030693
Email whh900710@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary dysmenorrhea is a common under-diagnosed complaint, with a prevalence of about 45-95% in women of childbearing age and about 10-25% in severe cases. Menstrual pain can be classified as primary or secondary. Primary menstrual pain is a crampy pain in the lower abdomen without any pelvic pathology, which usually occurs 6 to 12 months after the first menstruation. Primary menstrual pain is usually most severe on the first day of the menstrual cycle and lasts for 8 to 72 hours. The cause is still unknown, but studies suggest that it may be related to increased prostaglandins, which cause painful contractions of the uterus. The pain is often accompanied by other menstrual discomfort symptoms, including headache, breast tenderness, drowsiness, nausea, vomiting, constipation or diarrhea, and psychological anxiety, depression or irritability. In the case of secondary menstrual pain, there are clear pelvic pathologies, such as endometriosis, uterine fibroids, and pelvic inflammatory disease.


Description:

In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400, while the placebo was 1/20 concentration of nuan-gong-ye plus glycerin and PEG400, all from the same batch. A bottle of nuan-gong-ye will be taken for HPLC fingerprint to examine its components. A total of 140 people will be divided randomly into two groups, of which the experimental group using nuan-gong-ye and the control group using a placebo. Four menstrual cycles of the clinical trial will be conducted after recruitment. The first menstrual cycle will be non-interventional, with subjects filling out Basic information sheet, Visual Analogue Scale (VAS), and Short Form McGill Pain Questionnaire (MPQ-SF). In the second to fourth menstrual cycles, two bottles of approximately 16 ml of nuan-gong-ye will be applied. During these three cycles, the application will begin five days before each menstrual period and end on the third day of the menstruation, with the VAS, McGill scale, and side effects questionnaire being completed. The skin should be dry before application. For each application of nuan-gong-ye or placebo, apply 10 circles clockwise from the navel to a circular area with a radius of 8 to 13 cm. The first application will be done after waking up, the second and third apply every five hours, and the fourth apply at bedtime, for a total of four applications a day. Other relief measures such as Chinese medicine, hot compresses, abdominal massage, acupuncture, and the use of other essential oils are prohibited during the research period, while painkillers are not.


Recruitment information / eligibility

Status Recruiting
Enrollment 82
Est. completion date February 28, 2026
Est. primary completion date August 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria: - 20-40 year-old women - Regular menstrual cycle of 21-35 days, with menstruation lasting 3-7 days - Dysmenorrhea started before the age of 20, and have menstrual pain every month - No organic lesions on ultrasound within one year (either abdomen or vagina) - VAS score above 4 - Agree to participate in the study and sign the consent form Exclusion Criteria: - Has used the same formula of Nuan-gong-ye before. - Allergic to Nuan-gong-ye. - Has abdominal wounds, infections, or skin diseases. - Pregnant or planning to become pregnant within the next five months. - Has taken traditional Chinese medicine or prescribed medication for menstrual pain by a Chinese medicine doctor in the past month. - Has major illnesses defined by the Taiwan National Health Insurance Administration, such as cancer, heart disease, etc. - Has mental illness or cognitive impairment and cannot independently fill out the questionnaire. - Has a history of epilepsy or pelvic disorders.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nuan-gong-ye
In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400.
Other:
Placebo
The placebo was 1/20 concentration of nuan-gong-ye plus glycerin and PEG400.

Locations

Country Name City State
Taiwan China Medical University Hospital Taichung

Sponsors (1)

Lead Sponsor Collaborator
China Medical University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Analogue Scale (VAS) The intensity of menstrual pain was measured by the Visual Analogue Scale (VAS). The VAS scale is a continuous horizontal line ten centimeters in length. The left end of the line, marked as 0, represents 'no pain,' while the right end, marked as 10, represents 'the most intense pain'. The VAS and McGill scales were used to assess the difference before and after each menstrual cycle. 4 months
Secondary Short Form McGill Pain Questionnaire (MPQ-SF) Pain perception was measured by the Short Form McGill Pain Questionnaire (MPQ-SF). The scale consists of 15 items, with scores ranging from 0 to 3 to assess the intensity of each pain. 0 represents 'none,' 1 represents 'mild pain,' 2 represents 'moderate pain,' and 3 represents 'severe pain.' The VAS and McGill scales were used to assess the difference before and after each menstrual cycle. 4 months
See also
  Status Clinical Trial Phase
Completed NCT03594916 - Efficacy of Transcranial Direct Current Stimulation for Severe Primary Dysmenorrhea N/A
Completed NCT03608215 - Neuromodulatary Efficacy of Transcranial Direct Current Stimulation in Severe Refractory Primary Dysmenorrhea N/A
Not yet recruiting NCT04541134 - Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea Phase 3
Completed NCT04083131 - Sense of Coherence and Primary Dysmenorrhea in High School Girls in Finistere, France
Not yet recruiting NCT05448027 - Low Versus High Intensity Laser Therapy on Primary Dysmenorrhea N/A
Completed NCT04662814 - Extracorporeal Shock Wave Therapy for Dysmenorrhea N/A
Recruiting NCT05771753 - Comparison of Core Stabilization and Dynamic Stretching Exercises in Primary Dysmenorrhea N/A
Not yet recruiting NCT04665661 - Aerobic Exercise for Primary Dysmenorrhea N/A
Completed NCT03290066 - Effectiveness of Kinesiotaping in Primary Dysmenorrhea N/A
Completed NCT03593850 - Music for Pain in Primary Dysmenorrhea N/A
Completed NCT04235595 - Comparison of the Effects of TENS and CTM on Primary Dysmenorrhea N/A
Completed NCT05081869 - Investigation of the Effect of Online Yoga Based Exercise Program on Women With Primary Dysmenorrhea N/A
Not yet recruiting NCT06398990 - The Effect of Cognitive Exercise Therapy Approach and Yoga in Adolescents With Dysmenorrhoea N/A
Completed NCT02026206 - Low-level Light Therapy for Primary Dysmenorrhea Phase 3
Completed NCT05686460 - Effect of Hegu Point Ice Massage and Music in Dysmenorrhea N/A
Not yet recruiting NCT06052722 - The Relationship of Premenstrual Syndrome and Primary Dysmenorrhea With Severity of Temporomandibular Disorders N/A
Completed NCT04119011 - Probiotics in Women With Primary Dysmenorrhoea Phase 1/Phase 2
Active, not recruiting NCT05938660 - Effects of Acupressure at Sanyinjiao Point on Primary Dysmenorrhea Among University Students. N/A
Completed NCT04856280 - Kinesiological Taping and Aerobic Exercise in Women With Primary Dysmenorrhea: N/A
Completed NCT02602522 - Danshen-Jiang-Fu Granule Prepared by Danshen From Different Producing Areas for Primary Dysmenorrhea Early Phase 1